clinical trial · NCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Merck Sharp & Dohme LLC·phase2·active not recruiting·n = 140
Relapsed or Refractory Diffuse Large B-Cell LymphomaZilovertamab vedotin
brief summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
started
Jan 8, 2022
primary completion
Apr 22, 2026
completion
Apr 22, 2026
last updated
Feb 13, 2026
official title
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol